الصفحة الرئيسية>>Signaling Pathways>> PROTAC>>Thalidomide 4'-oxyacetamide-PEG3-amine

Thalidomide 4'-oxyacetamide-PEG3-amine

رقم الكتالوجGC50462

ثاليدوميد 4' ؛-أوكسي أسيتاميد- PEG3- أمين هو اتحاد مركب E3 يجاز ليجاند رابط يشتمل على ليجند cereblon القائم على ثاليدوميد ورابط PEG ثلاثي الوحدات المستخدم في تقنية PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

Thalidomide 4'-oxyacetamide-PEG3-amine التركيب الكيميائي

Cas No.: 2245697-84-9

الحجم السعر المخزون الكميّة
25mg
84٫00
متوفر
100mg
245٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Functionalized cereblon ligand for PROTACsup>® research and development; incorporates an E3 ligase ligand plus a PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 1 PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Winter et al (2015) Functionalized Cereblon ligand for PROTACs; incorporates an E3 ligase ligand and a linker used in PROTAC technology. Science 348 1376 PMID:25999370 |Salami et al (2017) Waste disposal-An attractive strategy for cancer therapy. Science 355 1163 PMID:28302825

مراجعات

Review for Thalidomide 4'-oxyacetamide-PEG3-amine

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thalidomide 4'-oxyacetamide-PEG3-amine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.